Soluble TIM-3, likely produced by myeloid cells, predicts resistance to immune checkpoint inhibitors in metastatic clear cell renal cell carcinoma

Abstract Background Immunotherapies targeting PD-1 and CTLA-4 are key components of the treatment of metastatic clear cell renal cell carcinoma (mccRCC). However, they have distinct safety profiles and resistance to treatment can occur. We assess soluble TIM-3 (sTIM-3) in the plasma of mccRCC patien...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ivan Pourmir, Nadine Benhamouda, Thi Tran, Hugo Roux, Joséphine Pineau, Alain Gey, Andyara Munoz, Nesrine Mabrouk, Nicolas Epaillard, Virginie Verkarre, Yann-Alexandre Vano, Eric Tartour, Stéphane Oudard
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BMC 2025-02-01
Edice:	Journal of Experimental & Clinical Cancer Research
Témata:	Clear cell renal cell carcinoma Soluble TIM-3 Myeloid cells Biomarkers Immunotherapy Immune checkpoints
On-line přístup:	https://doi.org/10.1186/s13046-025-03293-y
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!